SCHEMBL7130925

SCHEMBL7130925

NCCOc1ccc2c(c1)C(S(=O)(=O)c1ccccc1)CS2(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.39
ITGA2B P08514 2/20 0.39
TAAR1 Q96RJ0 1/20 0.37
LTA4H P09960 2/20 0.37
PLA2G2A P14555 1/20 0.37
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA9 Q16790 3/20 0.36
CYP19A1 P11511 2/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
SLC10A2 Q12908 1/20 0.34
FGFR1 P11362 1/20 0.33
HTR2A P28223 1/20 0.33
F2 P00734 3/20 0.33
PDK2 Q15119 1/20 0.33
CYP3A4 P08684 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CA12 O43570 1/20 0.32
CA7 P43166 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7161197 0.99 ITGB3 (0.38) ITGB3ITGA2BTAAR1LTA4HPLA2G2A
SCHEMBL7135475 0.91 CA1 (0.41) ITGB3ITGA2BTAAR1LTA4HPLA2G2A
SCHEMBL7133298 0.91 KAT6A (0.37) CA1CA2CA9SLC10A2F2
Hydrochloric Acid SCHEMBL7160723 0.90 CA1 (0.40) ITGB3ITGA2BTAAR1LTA4HPLA2G2A
SCHEMBL7132809 0.88 SLC10A2 (0.37) ITGB3ITGA2BCA1CA2CA9
SCHEMBL7130918 0.88 ITGB3 (0.40) ITGB3ITGA2BTAAR1LTA4HPLA2G2A
SCHEMBL7131499 0.87 SLC10A2 (0.43) LTA4HCA1CA2CA9SLC10A2
Hydrochloric Acid SCHEMBL7161203 0.87 ITGB3 (0.40) ITGB3ITGA2BTAAR1LTA4HPLA2G2A
SCHEMBL7132188 0.86 TAAR1 (0.39) ITGB3ITGA2BTAAR1LTA4HPLA2G2A
SCHEMBL7689836 0.86 KDM4E (0.46) LTA4HESR1ESR2SLC10A2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO ITGB3 3260/4885ITGA2B 2276/4885TAAR1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.